Fundraising Fox

Endeavor Biomedicines

San Diego, US · Founded 2018 · Delaware corporation · 52 employees on LinkedIn · 2 known investors

Find your way into Endeavor Biomedicines

156 people in our graph share verified history with the Endeavor Biomedicines team — schools, employers, funds. One of them is your warm intro.

Lisa Robertsunlockedknows John Hood · together at Texas A&M University (overlapped)
×6knows the team · via Texas A&M University
×5knows the team · via The Scripps Research Institute

Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.

Founders & leadership

Endeavor Biomedicines was founded in 2018 by John Hood.

JHJohn Hood
John HoodinFounder and Executive ChairmanHe previously founded and led Impact Biomedicines as CEO, co-founded Samumed as its chief scientific officer, and served as director of research at TargeGen. His earlier career included a research fellowship at The Scripps Research Institute.
WC
Wing Cheong LamNamed on SEC filing
BD
Bernard DavitianNamed on SEC filing
RS
Raghu SaripalliNamed on SEC filing
MMMonal Mehta
Monal MehtainBoard Member2022–2025Venture Partner at Versant Ventures
MDMiguel de los Rios
Miguel de los RiosinFounder, President and Chief Scientific OfficerA co-founder of the company, he served as its president and CEO before moving into the scientific leadership role. He previously founded and led RIFT Biotherapeutics and Chimeros, and headed research and development at Sevion Therapeutics and Fabrus.

Board

PGPatrick G. Enright
Patrick G. EnrightinBoard MemberManaging Director at Longitude Capital

Investors · 2

Reported raises · per SEC filings

Form D private placements

$221.7M disclosed across 2 rounds · 2022–2024

$132.6MraisedMay 2024 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick G. EnrightDirector
  • Bernard DavitianDirector
  • John HoodExecutive Officer, Director
  • Vishaal TurakhiaExecutive Officer
  • Chris KruegerExecutive Officer
  • Enoch KariukiExecutive Officer
  • Karan TakharDirector
  • Miguel de los RiosExecutive Officer
  • Monal MehtaDirector
  • Wing Cheong LamDirector
Offering amount
$132.6M
Amount sold
$132.6M
First sale
Apr 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$89.1MraisedFeb 2022 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Wing Cheong LamDirector
  • Bernard DavitianDirector
  • Raghu SaripalliExecutive Officer
  • John HoodDirector, Executive Officer
  • Monal MehtaDirector
  • Patrick G. EnrightDirector
  • Miguel de los RiosExecutive Officer
Offering amount
$101M
Amount sold
$89.1M
First sale
Jan 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Companies competing with Endeavor Biomedicines for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Endeavor Biomedicines do?
Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.
Who founded Endeavor Biomedicines?
Endeavor Biomedicines was founded by John Hood in 2018.
Who are Endeavor Biomedicines's investors?
Endeavor Biomedicines's investors include Fidelity Investments, Longitude Capital.
How much funding has Endeavor Biomedicines raised?
Endeavor Biomedicines has disclosed $221.7M raised across 2 rounds.
Where is Endeavor Biomedicines headquartered?
Endeavor Biomedicines is headquartered in San Diego, US.